Active or pending CTN protocols:

CTN Protocol

Study Title (* indicates active enrollment)

  • Clinical sites and Principal Investigators


Medication Treatment for Opioid-dependent Expecting Mothers (MOMs): A Pragmatic Randomized Trial Comparing Two Buprenorphine Formulations.*


Emergency Department-INitiated bupreNOrphine and VAlidaTIOn Network Trial (ED-INNOVATION).*


Optimizing Retention, Duration, and Discontinuation (RDD) Strategies for Opioid Use Disorder Pharmacotherapy.


Subthreshold Opioid Use Disorder Prevention (STOP) Trial.


Addressing Opioid & Pain Stigma in Cancer Survivors.


Impact of social distancing measures, expansion of telemedicine for buprenorphine prescribing, and health insurance payor on access tobuprenorphine during the COVID-19 pandemic.


Contributions to other CTN activities:

Rural Special Interest Group: Co-chaired by Erin Winstanley and attended by Sarah Kawasaki and Judith Feinberg. The goal of ththis group is to facilitate research on service delivery and outcomes among patients with substance use disorders who reside in rural areas. The long-term goal is to improve the implementation of empirically-based treatment services in rural areas.

Comorbidities Special Interest Group: Co-chaired by Judith Feinberg and attended by Antoine Douaihy. This was formerly the HIV Special Interest Group and has been broadened to cover other significant infections (e.g., viral hepatitis, endocarditis) that occur among people who use drugs as well as co-occurring mental health issues in this population.

Minority Special Interest Group: Attended by Deanna Wilson. This group focuses on increasing opportunities for emerging scholars from underrepresented minority groups through involvement in research and mentoring throughout the node, increasing diversity and inclusion in the RDC, and methodological concerns focused on enhancing information derived from CTN protocols on racial/ethnic groups.

Methadone Task Force: Attended by Sarah Kawasaki and Jane Liebschutz. The goal of this task force is to identify best practices and models for delivering methadone maintenance in office-based or community-based settings. 

Stimulant Research Task Force: Attended by Laura Lander; Antoine Douaihy; Sarah Kawasaki. No FDA-approved treatment exists for treating stimulant use disorders and the role of this task force is to develop a CTN strategic plan to prioritize research in this area and identify interventions that will improve health outcomes among individuals with stimulant use disorders.

Clinical Informatics/Artificial Intelligence Workgroup: Attended by Jason Colditz. This group explores opportunities for integrating novel data science methods (e.g., machine learning, predictive and prognostic modeling) and integration complex data streams (e.g., clinical trial datasets, electronic health records, mobile health data) into addiction research contexts.